Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections
Prevalence Of Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Urinary tract infection is among the most common nosocomial and community acquired infections. The Information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy .Resistance to antibiotic treatment in patients with urinary tract infections (UTIs) is a representative example of the increasing problem of antimicrobial resistance. Extended-spectrum β-lactamases (ESBLs) has emerged as an important mechanism of resistance in Gram-negative bacteria.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 7, 2021
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedFirst Posted
Study publicly available on registry
December 2, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2022
CompletedDecember 2, 2021
November 1, 2021
5 months
October 7, 2021
November 18, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
The aim of this study is to indicate the spread of extended spectrum beta lactamase producing gram negative bacteria ( that isolated from the urine of patients with urinary tract infections based on their susceptibility to antimicrobial agents )
This study will be conducted on a group of patients who are diagnosed that have urinary tract infections . * Methods of the study: Antibiotic susceptibility will be examined on disk diffusion test on Mueller-Hinton agar (MHA) . The zones of growth inhibition around each of the antibiotic disks are measured to the nearest millimeter
through study completion, an average of 1 year
The aim of this study is to indicate the spread of extended spectrum beta lactamase producing gram negative bacteria ( that isolated from the urine of patients with urinary tract infections based on their susceptibility to antimicrobial agents )
This study will be conducted on a group of patients who are diagnosed that have urinary tract infections . * Methods of the study: Antibiotic susceptibility will be performed by automated method Vitek -2 system that measured by minimal inhibitory concentration (MIC) .
through study completion, an average of 1 year
Eligibility Criteria
This study will be conducted on all patients who are diagnosed that have urinary tract infections
You may qualify if:
- This study will be conducted on a group of patients who are diagnosed that have urinary tract infections
You may not qualify if:
- The cases that do not give bacterial growth .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident of Clinical and Chemical Pathology
Study Record Dates
First Submitted
October 7, 2021
First Posted
December 2, 2021
Study Start
December 1, 2021
Primary Completion
May 1, 2022
Study Completion
November 1, 2022
Last Updated
December 2, 2021
Record last verified: 2021-11